Filtered By:
Drug: Methotrexate

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 117 results found since Jan 2013.

Updates in the diagnosis and management of Takayasu's arteritis
This article aims to describe to the reader key features of Takayasu's arteritis and highlights updated evidence in the diagnosis and management of these patients. We also review the 2021 ACR guidelines for Takayasu's arteritis and correlate them to the updated evidence discussed throughout the review. An extensive literature search was conducted via PUBMED, including the words 'Takayasu's diagnostic criteria,' 'Takayasu's treatment,' 'Takayasu's diagnosis,' 'Takayasu's imaging', and 'Takayasu's diagnostic criteria.' Search was filtered to include clinical trials, randomized controlled trials, systematic reviews, and meta-...
Source: Postgraduate Medicine - January 2, 2023 Category: Internal Medicine Authors: Anupam Somashekar Yiu Tak Leung Source Type: research

Methotrexate-Induced Stroke-Like Encephalopathy: Beware the Stroke Mimic
We report a case of methotrexate (MTX)-induced stroke-like encephalopathy in an 18-year-old woman, with acute lymphoblastic leukemia, who developed a sudden neurological deficit mimicking a cerebrovascular event. Bain MRI showed hyperintensities on diffusion-weighted-imaging (DWI) with matching apparent diffusion coefficient hypointensities, which also represent the commonest MRI findings in acute cerebral infarction. DWI changes spared the cerebral cortex and did not respect vascular territories, supporting a non-vascular mechanism. MRI plays a crucial role in the diagnostic work-up   and is essential to avoid unnecessar...
Source: Journal of the Belgian Society of Radiology - October 31, 2022 Category: Radiology Source Type: research

Psoriasis a Cause of Cardiovascular Diseases: A Review Article
Cureus. 2022 Aug 8;14(8):e27767. doi: 10.7759/cureus.27767. eCollection 2022 Aug.ABSTRACTPsoriasis is a severe, chronic inflammatory disease characterized by erythematous plaques across the extensor surfaces of the skin. Psoriasis has been linked to a higher threat of vascular events like myocardial infarction and stroke. Other associated cardiovascular disorders in the case of psoriasis include building up atherosclerosis, non-ischemic dilated cardiomyopathy, and psoriatic arthritis. Individuals can use International Classification of Diseases (ICD-9) codes to identify cardiovascular disease/comorbidities and related risk...
Source: Atherosclerosis - September 15, 2022 Category: Cardiology Authors: Aditi Gupta Bhushan Madke Source Type: research

Examining anti-inflammatory therapies in the prevention of cardiovascular events: protocol for a systematic review and network meta-analysis of randomised controlled trials
Introduction Inflammation is emerging as an important risk factor for atherosclerotic cardiovascular disease and has been a recent target for many novel therapeutic agents. However, comparative evidence regarding efficacy of these anti-inflammatory treatment options is currently lacking. Methods and analysis This systematic review will include randomised controlled trials evaluating the effect of anti-inflammatory agents on cardiovascular outcomes in patients with known cardiovascular disease. Studies will be retrieved from Medline, Embase, the Cochrane Central Register of Controlled Trials, as well as clinical trial regi...
Source: BMJ Open - June 27, 2022 Category: General Medicine Authors: Boczar, K. E., Shin, S., Bezzina, K. A., Geejo, A., Pearson, A. L., Shahab, S., Fehlmann, C. A., Visintini, S., Beanlands, R., Wells, G. A. Tags: Open access, Cardiovascular medicine Source Type: research

The Clinical Impact of Methotrexate-Induced Stroke-Like Neurotoxicity in Paediatric Departments: An Italian Multi-Centre Case-Series
ConclusionsSLS is a rare, well-characterized complication of MTX administration. Despite the small sample, we have been able to confirm some of the previous findings in literature. We also identified a linear correlation between age and severity of the disease, which could improve the future clinical management.
Source: Frontiers in Neurology - June 10, 2022 Category: Neurology Source Type: research

Immune Pathways in Etiology, Acute Phase, and Chronic Sequelae of Ischemic Stroke
Circ Res. 2022 Apr 15;130(8):1167-1186. doi: 10.1161/CIRCRESAHA.121.319994. Epub 2022 Apr 14.ABSTRACTInflammation and immune mechanisms are crucially involved in the pathophysiology of the development, acute damage cascades, and chronic course after ischemic stroke. Atherosclerosis is an inflammatory disease, and, in addition to classical risk factors, maladaptive immune mechanisms lead to an increased risk of stroke. Accordingly, individuals with signs of inflammation or corresponding biomarkers have an increased risk of stroke. Anti-inflammatory drugs, such as IL (interleukin)-1β blockers, methotrexate, or colchicine, r...
Source: Atherosclerosis - April 14, 2022 Category: Cardiology Authors: Matthias Endres Maria A Moro Christian H Nolte Claudia Dames Marion S Buckwalter Andreas Meisel Source Type: research

Progression of Large Vessel Disease in Patients With Giant Cell Arteritis–Associated Ischemic Stroke: The Role of Vascular Imaging: A Case Series
Conclusions Vascular imaging, especially with color-coded duplex sonography, could play a role in the follow-up of patients with GCA-related IS and identify those patients with higher risk of recurrent stroke.
Source: JCR: Journal of Clinical Rheumatology - December 1, 2021 Category: Rheumatology Tags: Original Articles Source Type: research

Diagnostics and treatment of giant cell arteritis
Nervenarzt. 2021 Nov 3. doi: 10.1007/s00115-021-01216-8. Online ahead of print.ABSTRACTGiant cell arteritis (GCA) is the most common idiopathic systemic vasculitis in the age group over 50 years. It requires prompt diagnostics and treatment to avoid severe complications, such as visual loss or stroke. The tendency to relapse makes a glucocorticoid (GC) treatment necessary for several years and sometimes lifelong, which increases the risk of GC-induced long-term side effects. Therefore, additive GC-sparing treatment is recommended in the majority of patients. For this purpose, the anti-IL‑6 receptor antibody tocilizumab i...
Source: Der Nervenarzt - November 4, 2021 Category: Neurology Authors: Markus Kraemer Jana Becker Thorsten Alexander Bley Andreas Steinbrecher Jens Minnerup Bernhard Hellmich Source Type: research